Skip to main content
. 2017 May 15;6(1):175–186. doi: 10.1007/s40123-017-0091-9

Fig. 2.

Fig. 2

Patients in the anti-VEGF-naïve cohort (n = 27) achieving VA gains (in ETDRS letters) after 12 months of treatment with ranibizumab on the T&E regimen. ETDRS Early Treatment Diabetic Retinopathy Study, T&E treat and extend, VEGF vascular endothelial growth factor